翰森制药(03692) - 2022 - 年度业绩

Financial Performance - The company reported a revenue of approximately RMB 9.382 billion for the year ended December 31, 2022, a decrease of about 5.6% compared to the previous year[1]. - The company's profit was approximately RMB 2.584 billion, a decrease of about 4.8% compared to the previous year[1]. - Earnings per share were approximately RMB 0.44, down about 4.7% from the previous year[1]. - Total revenue for the year ended December 31, 2022, was approximately RMB 9.382 billion, a decrease of about 5.6% compared to the previous year, while profit was approximately RMB 2.584 billion, down about 4.8% year-on-year[9]. - Gross profit for 2022 was RMB 8,515,400, down from RMB 9,065,099 in 2021, reflecting a gross margin of approximately 90.7%[36]. - The group reported a pre-tax profit of RMB 2,596,470,000 in 2022, an increase from RMB 2,370,408,000 in 2021, reflecting a growth of approximately 9.5%[45]. - The total tax expense for the year was RMB 364,681,000, down from RMB 587,180,000 in 2021, indicating a reduction of about 37.9%[48]. - The company’s attributable profit for 2022 was RMB 2,583,747 thousand, a decrease from RMB 2,712,902 thousand in 2021, representing a decline of approximately 4.7%[50]. Revenue Breakdown - Sales revenue from innovative drugs reached approximately RMB 5.006 billion, an increase of about 19.1%, accounting for 53.4% of total revenue, up from 42.3% in the previous year[1][2]. - Revenue from the oncology drug portfolio reached approximately RMB 5.522 billion, accounting for about 58.9% of the total revenue[9]. - Revenue from the central nervous system disease product portfolio reached approximately RMB 1.494 billion, accounting for about 15.9% of total revenue[10]. - Revenue from the anti-infection product portfolio reached approximately RMB 1.249 billion, accounting for about 13.3% of total revenue[10]. - Revenue from the metabolic and other product portfolio reached approximately RMB 1.117 billion, accounting for about 11.9% of total revenue[10]. - Revenue from customer contracts for goods sales decreased to RMB 9,298,594,000 in 2022 from RMB 9,707,761,000 in 2021, representing a decline of approximately 4.2%[44]. Research and Development - Research and development expenses were approximately RMB 1.693 billion, representing about 18.0% of total revenue[1]. - The company has a total of over 30 innovative drug projects at various clinical stages, with 1,521 research personnel dedicated to enhancing independent innovation and research efficiency[9]. - The company submitted six new drug applications, including one for a Class 1 innovative drug, during the reporting period[2]. - The company has established a research and development team of 1,521 researchers across four centers in China and the U.S., focusing on oncology, infectious diseases, CNS disorders, metabolic diseases, and autoimmune diseases[18]. - The innovative drug pipeline achieved significant progress, with two approved indications for Amelior being included in the national medical insurance catalog[11]. Licensing and Partnerships - The company entered into an exclusive licensing agreement with NiKang Therapeutics for the development and commercialization of NKT2152 in China[3]. - The company entered into exclusive licensing agreements for the development and commercialization of several drugs, including PM1080 for EGFR/cMet dual-specificity antibody and TU2670 for endometriosis and uterine fibroids[5][8]. - The company has established a partnership with EQRx for the global development and commercialization of GDI4405, a candidate drug for COVID-19[4]. - The company has established a partnership with TiumBio to develop and commercialize TU2670 for the treatment of endometriosis and uterine fibroids in China[26]. - The company has obtained exclusive rights to develop, produce, and commercialize the candidate drug GDI-4405 series for COVID-19 globally through a partnership with GHDDI[27]. Market Presence and Product Approvals - The company has five Class 1 innovative drugs and one imported innovative drug approved for market in China, with eleven products approved during the reporting period[2]. - The company received drug registration certificates for six innovative drugs, all of which entered the national medical insurance catalog by the end of the reporting period[9]. - Four innovative drugs have been included in the National Medical Insurance Catalog (2022 version), enhancing the company's market presence[57]. - The innovative drug Fulaimei, a long-acting GLP-1 analog, was recognized in the diabetes treatment guidelines as a new medication option[15]. - The innovative drug Ianalumab injection (brand name: Xinyue®) was approved for marketing in March 2022 for the treatment of adult patients with AQP4 antibody-positive NMOSD[19]. Corporate Governance and Sustainability - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and internal controls[61]. - The company has adopted a customized code of conduct for directors regarding securities trading, ensuring compliance with the standards set forth in the listing rules[60]. - The company has complied with all provisions of the corporate governance code during the reporting period, except for the separation of the roles of Chairman and CEO[59]. - The company received a score of 63 in the S&P Global Corporate Sustainability Assessment, surpassing 95% of its peers globally, and was recognized in the 2023 Sustainability Yearbook as the only selected pharmaceutical company from mainland China[30]. - The company maintains a strong commitment to ESG principles, focusing on corporate governance, product quality, and community progress, while receiving multiple awards for its sustainability efforts[30]. Cash Flow and Financial Position - The company achieved a net cash inflow of RMB 2.741 billion from operating activities for the year ended December 31, 2022, with capital expenditures of RMB 319 million primarily for construction and equipment purchases[31]. - As of December 31, 2022, the company had cash and bank deposits of RMB 17.615 billion, an increase from RMB 14.702 billion as of December 31, 2021, and a debt-to-asset ratio of approximately 24.5%[31]. - Current assets increased to RMB 25,831,620 in 2022 from RMB 23,179,368 in 2021, indicating a growth of 11.4%[38]. - The company's cash and bank balances decreased to RMB 1,463,752 in 2022 from RMB 1,873,773 in 2021, a decline of 21.8%[38]. - Trade receivables, net of impairment, increased to RMB 3,533,969 thousand in 2022 from RMB 3,247,297 thousand in 2021, reflecting a growth of approximately 8.8%[51]. Employee and Operational Metrics - The company employed a total of 10,523 full-time employees as of December 31, 2022, with employee costs amounting to approximately RMB 2.596 billion for the year[34]. - The company incurred approximately RMB 292 million in business development (BD) project expenses during the reporting period[22]. - The company has not engaged in any significant acquisitions or disposals during the reporting period[33].